Long-Term Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor-α Modulator (SPPARMα), in Dyslipidemic Patients with Renal Impairment
Open accessThe DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Abstract
Pemafibrate (K-877) is a novel selective peroxisome proliferator-activated receptor-α modulator (SPPARMα) with a favorable benefit-risk balance. Previous clinical trials of pemafibrate used stringent exclusion criteria related to renal functions. Therefore, we investigated its safety and efficacy in a broader range of patients, including those with chronic kidney disease (CKD). In this multicenter, single-arm, open-label, phase III trial, 0.2–0.4 mg/day pemafibrate was administered for 52 weeks to 189 patients with hypertriglyceridemia and an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 on statin or regardless of eGFR when statin was not administered. Post-hoc analyses were performed on subgroups stratified by baseline eGFR. Triglyceride levels decreased by 45.9% at week 52 (last-observation-carried-forward). These reductions were not correlated with baseline eGFR. The eGFR < 30 mL/min/1.73 m2 subgroup showed the greatest reduction in chylomicron, very low-density lipoprotein, small low-density lipoprotein cholesterol levels, and an increase in high-density lipoprotein cholesterol levels. The incidences of adverse events and adverse drug reactions were 82.0% and 31.7%, respectively, and these were not associated with baseline eGFR. In CKD patients, pemafibrate blood concentrations were not elevated. Pemafibrate showed a good safety profile and efficacy in correcting lipid abnormalities in a broad range of patients, including those with CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“No major increase in blood pemafibrate concentrations was observed even after administering repeated dosage [94].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach
Hebert, L. A., Parikh, S., Prosek, J., Nadasdy, T., & Rovin, B. H. (2013) · American Journal of Nephrology · doi:10.1159/000354390 · Cited by 4,376
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60674-5 · Cited by 4,200 · cited 1×
“Reduced renal function is associated with elevated risks of cardiovascular disease (CVD) and death [5,6].”
BackgroundMortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043 · cited 1×
“Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of death [1,2].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Andrassy, K. M. (2013) · Kidney International · doi:10.1038/ki.2013.243 · Cited by 2,496
Levey, A. S., de Jong, P. E., Coresh, J., El Nahas, M., Astor, B. C., Matsushita, K., Gansevoort, R. T., Kasiske, B. L., & Eckardt, K.-U. (2011) · Kidney International · doi:10.1038/ki.2010.483 · Cited by 2,345 · cited 1×
“Reduced renal function is associated with elevated risks of cardiovascular disease (CVD) and death [5,6].”
Background2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
Graham, D. J. (2004) · JAMA · doi:10.1001/jama.292.21.2585 · Cited by 875 · cited 2×
“Therefore, the concomitant use of these drugs should be avoided in these patients, whereas the risks vary with different fibrates and statins used in combination [20].”
Background
Cited by
Okamura, T., Tsukamoto, K., Arai, H., Fujioka, Y., Ishigaki, Y., Koba, S., Ohmura, H., Shoji, T., Yokote, K., Yoshida, H., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2022 · Cited by 302
Self-citationNonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Francque, S., Szabo, G., Abdelmalek, M. F., Byrne, C. D., Cusi, K., Dufour, J.-F., Roden, M., Sacks, F., & Tacke, F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00366-5 · Cited by 316
Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence
Cheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205055 · Cited by 264
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0823-5 · Cited by 191
Self-citationFruchart, J.-C., Santos, R. D., Aguilar-Salinas, C., Aikawa, M., Al Rasadi, K., Amarenco, P., Barter, P. J., Ceska, R., Corsini, A., Després, J.-P., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0864-7 · Cited by 140
Self-citationTreating NASH by targeting peroxisome proliferator-activated receptors
Staels, B., Butruille, L., & Francque, S. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.004 · Cited by 108
PPARα Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates
Kamata, S., Oyama, T., Saito, K., Honda, A., Yamamoto, Y., Suda, K., Ishikawa, R., Itoh, T., Watanabe, Y., Shibata, T., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101727 · Cited by 111
“In 2018, pemafibrate, which is also known as K-877 or SPPARMa (selective PPARa modulator), was approved in Japan as a highly PPARa-selective agonist that is safe for simultaneous use with statins, even in patients with mild kidney diseases (Yamashita et al., 2019, 2020; Yokote et al., 2019).”
BackgroundThibaut, R., Gage, M., Pineda‐Torra, I., Chabrier, G., Venteclef, N., & Alzaïd, F. (2021) · FEBS Journal · doi:10.1111/febs.15877 · Cited by 99
The PPAR–microbiota–metabolic organ trilogy to fine‐tune physiology
Oh, H. Y. P., Visvalingam, V., & Wahli, W. (2019) · The FASEB Journal · doi:10.1096/fj.201802681rr · Cited by 85
Apolipoprotein E–related glomerular disorders
Saito, T., Matsunaga, A., Fukunaga, M., Nagahama, K., Hara, S., & Muso, E. (2020) · Kidney International · doi:10.1016/j.kint.2019.10.031 · Cited by 77
Yamashita, S., Masuda, D., & Matsuzawa, Y. (2019) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.48918 · Cited by 66
Self-citationDyslipidemia in Chronic Kidney Disease: Contemporary Concepts and Future Therapeutic Perspectives
Theofilis, P., Vordoni, A., Koukoulaki, M., Vlachopanos, G., & Kalaitzidis, R. (2021) · American Journal of Nephrology · doi:10.1159/000518456 · Cited by 64
MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists
Cooreman, M. P., Vonghia, L., & Francque, S. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111688 · Cited by 58
Yamashita, S., Arai, H., Yokote, K., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225537 · Cited by 48
“Elevated plasma pemafibrate concentrations have not been noted in single-dose or repeated-dose studies of patients with renal dysfunction [14,15], or in drug-drug interaction studies of pemafibrate with various statins [16], suggesting that pemafibrate may represent a new drug category distinct from the conventional P…”
BackgroundSelf-citationYokote, K., Yamashita, S., Arai, H., Araki, E., Matsushita, M., Nojima, T., Suganami, H., & Ishibashi, S. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01291-w · Cited by 52
Self-citationGinsberg, H. N., Hounslow, N. J., Senko, Y., Suganami, H., Bogdanski, P., Ceska, R., Kalina, A., Libis, R. A., Supryadkina, T. V., & Hovingh, G. K. (2022) · Diabetes Care · doi:10.2337/dc21-1288 · Cited by 48
Self-citationMottl, A. K., Buse, J. B., Ismail-Beigi, F., Sigal, R. J., Pedley, C. F., Papademetriou, V., Simmons, D. L., Katz, L., Mychaleckyj, J. C., & Craven, T. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06200518 · Cited by 48
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 44
“Pemafibrate administration for long term was shown effective and safe in dyslipidemic patients, including those with renal dysfunction [67].”
BackgroundSelf-citationSasaki, Y., Raza-Iqbal, S., Tanaka, T., Murakami, K., Anai, M., Osawa, T., Matsumura, Y., Sakai, J., & Kodama, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225682 · Cited by 43
Association of NAFLD/NASH, and MAFLD/MASLD with chronic kidney disease: an updated narrative review
Lonardo, A. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.07 · Cited by 36
Horinouchi, Y., Murashima, Y., Yamada, Y., Yoshioka, S., Fukushima, K., Kure, T., Sasaki, N., Imanishi, M., Fujino, H., Tsuchiya, K., et al. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121590 · Cited by 32
Fruchart, J., Hermans, M. P., Fruchart‐Najib, J., & Kodama, T. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00897-x · Cited by 30
Vyletelová, V., Nováková, M., & Pašková, Ľ. (2022) · Pharmaceuticals · doi:10.3390/ph15101278 · Cited by 30
Sugimoto, R., Iwasa, M., Eguchi, A., Tamai, Y., Shigefuku, R., Fujiwara, N., Tanaka, H., Kobayashi, Y., Ikoma, J., Kaito, M., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1073025 · Cited by 27
Aomura, D., Harada, M., Yamada, Y., Nakajima, T., Hashimoto, K., Tanaka, N., & Kamijo, Y. (2021) · Metabolites · doi:10.3390/metabo11060372 · Cited by 21
Zhang, Z., Diao, P., Zhang, X., Nakajima, T., Kimura, T., & Tanaka, N. (2022) · Biomedicines · doi:10.3390/biomedicines10071667 · Cited by 21
Hypercaloric Diet Promotes Metabolic Disorders and Impaired Kidney Function
Meléndez-Salcido, C. G., Ramírez-Emiliano, J., & Pérez‐Vázquez, V. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612829666221020162955 · Cited by 21
Nakamura, A., Kagaya, Y., Saito, H., Kanazawa, M., Sato, K., Miura, M., Kondo, M., & Endo, H. (2022) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.63659 · Cited by 20
Kawanishi, H., Ohashi, K., Ogawa, H., Otaka, N., Takikawa, T., Fang, L., Ozaki, Y., Takefuji, M., Murohara, T., & Ouchi, N. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235362 · Cited by 19
Fruchart, J., Hermans, M. P., & Fruchart‐Najib, J. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00860-w · Cited by 19
Environmental Factors Modifying HDL Functionality
Kostara, C. E., Kosmas, C. E., Sourlas, A., & Guzman, E. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714155422 · Cited by 18
SPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 19
Yanai, H., Katsuyama, H., & Hakoshima, M. (2022) · Biomedicines · doi:10.3390/biomedicines10020401 · Cited by 17
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
Self-citationShaik, A., & Rosenson, R. S. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07168-0 · Cited by 16
“Pemafibrate has been shown to be effective and safe in reducing TG levels in patients with chronic kidney disease, regardless of estimated glomerular filtration rate (eGFR), with similar incidences of adverse events across eGFR groups [137].”
BackgroundSuto, K., Fukuda, D., Shinohara, M., Ganbaatar, B., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.61101 · Cited by 15
Yamashita, S., Okazaki, M., Okada, T., Masuda, D., Yokote, K., Arai, H., Araki, E., & Ishibashi, S. (2021) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.60764 · Cited by 14
Self-citationResearch advances in current drugs targeting hyperlipidemia (Review)
Zhao, H., Wang, Y., Li, Y., Cheng, R., & Chen, W. (2025) · Molecular Medicine Reports · doi:10.3892/mmr.2025.13623 · Cited by 15
Yamashita, S., Hirano, T., Shimano, H., Tsukamoto, K., Yoshida, M., & Yoshida, H. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14227 · Cited by 14
Self-citationTanaka, A., Nakamura, T., Sato, E., Chihara, A., & Node, K. (2020) · CEN Case Reports · doi:10.1007/s13730-020-00444-2 · Cited by 13
Nakano, T., Tanaka, S., Tsuruya, K., & Kitazono, T. (2021) · Clinical and Experimental Nephrology · doi:10.1007/s10157-020-02000-9 · Cited by 13
Efficacy and safety of pemafibrate in patients with chronic kidney disease: A retrospective study
Iwasaki, M., Suzuki, H., Umezawa, Y., Koshida, T., Saito, M., Fukuda, H., Takahara, H., Matsuzaki, K., & Suzuki, Y. (2023) · Medicine · doi:10.1097/md.0000000000032818 · Cited by 12
“Pema rarely causes adverse effects and is likely to be safe even in CKD patients owing to its biliary mode of excretion.[11,12] However, it remains unclear if Pema is safe and efficient in CKD patients.”
BackgroundThe role of PPARα in autosomal dominant polycystic kidney disease
Lakhia, R. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000615 · Cited by 14
Khan, M. S., Ghumman, G. M., Baqi, A., Shah, J., Aziz, M., Mir, T., Tahir, A., Katragadda, S., Singh, H., Taleb, M., et al. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00593-6 · Cited by 11
Iwaki, M., Kobayashi, T., Nogami, A., Ogawa, Y., Imajo, K., Sakai, E., Nakada, Y., Koyama, S., Kurihashi, T., Oza, N., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088862 · Cited by 11
Effect of Pemafibrate on Serum Creatinine in Patients with Chronic Kidney Disease
Imai, E., & Imai, A. (2022) · JMA Journal · doi:10.31662/jmaj.2021-0212 · Cited by 11
Hirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14076 · Cited by 10
“As shown in Figure 2a, sdLDL-C levels at baseline tended to be higher in the pema fi brate add-on group (pema fi brate add-on group: 55 mg/dL [43 – 63]; statin doubling group: 46 mg/dL [36 – 60]; P = 0.109), but this difference was not signi fi cant.”
BackgroundInfluentialOgawa, S.-I., Shimizu, M., & Yamazaki, H. (2020) · Xenobiotica · doi:10.1080/00498254.2019.1709133 · Cited by 10
“Pemafibrate (Figure 1) has been recently launched in Japan as an antidyslipidemic drug (Ishibashi et al., 2018; Yokote et al., 2019).”
BackgroundMetabolic Syndrome and Pharmacological Interventions in Clinical Development
Javor, E., Šarčević, D., & Rešić, A. (2024) · Diabetology · doi:10.3390/diabetology5030023 · Cited by 9
Primary biliary cholangitis: current insights and novel therapies
Granito, A., Παππάς, Γ., Napoli, L., Stefanini, B., Tirotta, D., & Muratori, P. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2672493 · Cited by 9
Dai, W., Lv, Q., Li, Q., Fu, L., Zhang, Y., Zhang, Y., Liu, L., Tanigawa, R., Kunitomi, K., Kamei, R., et al. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64112 · Cited by 9
Self-citationYanai, H., Katsuyama, H., & Hakoshima, M. (2021) · Cardiology Research · doi:10.14740/cr1333 · Cited by 9
Seki, M., Nakano, T., Tanaka, S., Matsukuma, Y., Funakoshi, K., Ohkuma, T., & Kitazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02322-4 · Cited by 8
“In a phase III trial, pemafibrate was safely administered to patients with renal failure—including dialysis-dependent patients—for 52 weeks, resulting in improved dyslipidemia [11].”
BackgroundAssociation between Pemafibrate Therapy and Triglyceride to HDL-Cholesterol Ratio
Imamura, T., Narang, N., & Kinugawa, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102820 · Cited by 7
Mae, Y., Takata, T., Taniguchi, S., Fujino, Y., Kageyama, K., Hanada, H., Iyama, T., Sugihara, T., & Isomoto, H. (2024) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2024.11.029 · Cited by 6
Komatsu, T., Miura, T., Joko, K., Sunohara, D., Mochidome, T., Kasai, T., & Ikeda, U. (2021) · Internal Medicine · doi:10.2169/internalmedicine.6871-20 · Cited by 6
“Patients with CKD often have atherogenic dyslipidemia, including high TG and low HDL-C, which occurs as a result of an impaired TG-rich lipoprotein catabolism associated with a decreased lipoprotein lipase activity or impaired HDL maturation caused by a reduced lecithin-cholesterol acyltransferase activity (21-25).”
BackgroundYamada‐Shimizu, M., Tamaki, N., Kurosaki, M., Uchihara, N., Suzuki, K., Tanaka, Y., Miyamoto, H., Ishido, S., Nobusawa, T., Matsumoto, H., et al. (2023) · Internal Medicine · doi:10.2169/internalmedicine.2248-23 · Cited by 6
“Because pemafibrate is a selective PRAR α modulator, it has the potential to have reduced side effects, such as hepatic and renal dysfunction, compared with conventional fibrate drugs (28).”
BackgroundArai, H., Yamashita, S., Araki, E., Yokote, K., Tanigawa, R., Saito, A., Furukawa, D., Suganami, H., & Ishibashi, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65350 · Cited by 5
Self-citationMinamizuka, T., Kobayashi, J., Tada, H., Miyashita, K., Koshizaka, M., Maezawa, Y., Ono, H., & Yokote, K. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.07.031 · Cited by 5
Self-citationKatakura, Y., Shimoda, M., Ohnishi, M., Kusano, T., Dan, K., Isobe, H., Wamata, R., Iwamoto, Y., Fushimi, Y., Sanada, J., et al. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.02.011 · Cited by 5
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
Ogawa, S.-I., Shimizu, M., & Yamazaki, H. (2020) · Xenobiotica · doi:10.1080/00498254.2020.1793030 · Cited by 4
Ishibashi, S., Arai, H., Yokote, K., Araki, E., Watanabe, M., Nakanishi, M., Makinose, Y., Suganami, H., Kurihara, Y., & Yamashita, S. (2024) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64887 · Cited by 3
Self-citationSchiel, M. A., Tosso, R. D., Angelina, E., García, A., Hennuyer, N., Cortés, D., Cabedo, N., & Enriz, R. D. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c01887 · Cited by 3
Peroxisome proliferator-activated receptors in kidney diseases: A promising therapeutic target
Li, Q., Shi, Z., Shi, X., Xing, H., Zhang, Y., Zhuang, S., & Chang, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.118983 · Cited by 3
Advances in the Pharmacologic Management of MASLD
Madhankumar, S., & Asma, A. (2026) · Gastroenterology Insights · doi:10.3390/gastroent17010017 · Cited by 2
Sucajtys-Szulc, E., Dębska-Ślizień, A. M., Rutkowski, B., Milczarek, R., Szołkiewicz, M., Świerczyński, J., & Smolenski, R. T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065733 · Cited by 2
“Moreover, recently published results indicated that pemafibrate, a novel selective PPARα activator, is a good and safe drug for treating serum lipid abnormalities in patients with CKD [50].”
BackgroundShima, H., Tashiro, M., Inoue, T., Okada, K., Okamoto, T., Wariishi, S., Doi, T., & Minakuchi, J. (2024) · Cureus · doi:10.7759/cureus.57777 · Cited by 2
Matsuoka‐Uchiyama, N., Uchida, H. A., Asakawa, T., Sakurabu, Y., Katayama, K., Okamoto, S., Onishi, Y., Tanaka, K., Takeuchi, H., Takemoto, R., et al. (2025) · Clinical and Experimental Nephrology · doi:10.1007/s10157-025-02640-9 · Cited by 1
Watanabe, Y., Nonaka, S., Yamaoka, S., Nakamura, S., Horikawa, O., Yamaguchi, T., Sato, S., Todani, S., Sugizaki, Y., Ito, T., et al. (2025) · Vascular Health and Risk Management · doi:10.2147/vhrm.s506642 · Cited by 1
Watanabe, M., Nakanishi, M., Shingaki, W., Gunji, R., Makinose, Y., Kanno, T., & Ishibashi, S. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03294-5 · Cited by 1
Self-citationNuclear receptors as therapeutic targets in metabolic and cardiovascular disorders
Li, F., Chen, Q., Dai, Y., & Lu, L. (2025) · iScience · doi:10.1016/j.isci.2025.114042 · Cited by 1
Hou, J., Li, Y., Lin, S., Liu, Q., Zheng, H., Liu, W., Wang, Y., Peng, L., & Wang, Z. (2026) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2026.5937 · Cited by 2
Kihara, H. (2022) · Journal of Nihon University Medical Association · doi:10.4264/numa.81.2_99 · Cited by 1
Pulipati, V. P., & Brinton, E. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00023-6
Brinton, E. A., & Pulipati, V. P. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_24
Okada, R., Onishi, Y., Kobayashi, N., Ishihara, H., Yokoyama, T., Mifune, T., Sakurabu, Y., Nojima, I., Morinaga, H., Uchida, H. A., et al. (2024) · Renal Replacement Therapy · doi:10.1186/s41100-024-00590-8
Peroxisome proliferator-activated receptors in metabolic and renal health: a comprehensive review
Vahora, N., Yathindra, M. R., James, D. M., Sharma, R., Panvalkar, A. S., Shyam, G., & Swathi, N. L. (2025) · International Journal of Research in Medical Sciences · doi:10.18203/2320-6012.ijrms20252817
Kinguchi, S., Tamura, K., Yano, Y., Nangaku, M., Isaka, Y., Maruyama, S., Kanegae, H., Heerspink, H. J. L., Nakagawa, N., Nishio, S., et al. (2026) · Clinical Kidney Journal · doi:10.1093/ckj/sfag053
Sato, T., Miyamoto, T., Fukuoka, R., Sugimoto, K., Tanimoto, Y., Nakayama, T., Tanimoto, K., Sugimura, K., Fujimoto, Y., Kiyooka, T., et al. (2026) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.66030
“Furthermore, previous clinical and preclinical studies have shown that pemafibrate effectively improves dyslipidemia while maintaining a favorable renal safety profile, even in patients with chronic kidney disease 24) .”
Kobuchi, S., NISHIDA, M., HAYAKAWA, M., MAEKAWA, Y., OHATA, A., CHIKAMI, S., IPPONMATSU, A., ITO, H., Moriwaki, A., Inose, R., et al. (2026) · In Vivo · doi:10.21873/invivo.14391
Metadata
- Authors
- Yokote, K., Yamashita, S., Arai, H., Araki, E., Suganami, H., & Ishibashi, S.
- Affiliations
- Chiba University (JP)
- Rinku General Medical Center (JP)
- National Center for Geriatrics and Gerontology (JP)
- Kumamoto University (JP)
- Kowa (Japan) (JP)
- Jichi Medical University (JP)
- Corresponding author
- Yokote, Koutaro
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-06
- Volume
- 20
- Issue
- 3
- Pages
- 706
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC6386904
- OpenAlex
- W2913672551
- Cited by
- 79
- References
- 48
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 12 · 2023: 14 · 2022: 9 · 2021: 12 · 2020: 10 · 2019: 9
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Kowa Company
- Japan Society for the Promotion of Science (17K19643, 17H04201, 17H02100, 18K08482)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- pemafibrate, PPARα modulator, chronic kidney disease, renal dysfunction, hypertriglyceridemia, dyslipidemia, triglyceride lowering, lipid-lowering therapy, drug safety, adverse drug reactions
- MeSH terms
- Aged, Benzoxazoles, Butyrates, Female, Humans, Kidney Function Tests, Lipids, Male, Middle Aged, Biomarkers, Treatment Outcome, PPAR alpha, Dyslipidemias, Renal Insufficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.